

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update – Surveillance Report 4

Search Results: May 2024


Systematic Review: Chou R, Ahmed AY, Bougatsos C, Morasco BJ, Gilbreath T, Dana T, Fu R. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 75Q80120D00006.) AHRQ Publication No. 23-EHC031. Rockville, MD: Agency for Healthcare Research and Quality; August 2023.

<https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/living-review>

Search Period: February 27, 2024, to April 28, 2024

Summary: During the current search period, one new study on cannabidiol (CBD) for temporomandibular disorders was identified for inclusion. Figure 1 shows the literature review process that identified all included studies. The new study was assessed as high risk of bias and had a small sample size (n=60). In addition, it evaluated a topical (oromucosal) low-tetrahydrocannabinol (THC) to CBD product, and it was unclear whether it was intended to have systemic effects. Therefore, it is not likely to change conclusions of the systematic review. The list of all studies identified since the 2023 systematic review is in Table 1, with the study identified during the current search period in bold.

Figure 1. Literature flow diagram



Note: Numbers in parentheses indicate all records identified up to the 2023 systematic review that had search dates through April 23, 2023. Numbers in brackets indicate the number of records identified since the systematic review was completed through April 28, 2024.

Table 1. New studies identified since the 2023 systematic review

Search Period	Citation	Risk of Bias	N Study Design
March 26 to April 28, 2024	Walczyńska-Dragon K, Kurek-Górecka A, Niemczyk W, et al. Cannabidiol intervention for muscular tension, pain, and sleep bruxism intensity—a randomized, double-blind clinical trial. <i>J Clin Med.</i> 2024;13(5). doi: 10.3390/jcm13051417.	High	60 Randomized controlled trial
January 1 to January 29, 2024	Holt A, Nouhravesh N, Strange JE, et al. Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study. <i>Eur Heart J.</i> 2024. doi: 10.1093/eurheartj/ehad834. PMID: 38200679	Moderate	32,332 Retrospective cohort
November 27 to December 31, 2023	Hansen JS, Boix F, Hasselstrom, J, et al. Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial. <i>Clin Transl Sci.</i> 2023b Dec 6;17(1):e13685. doi: 10.1111/cts.13685. PMID: 38054364.	Low (companion to Hansen, 2023a)	23 Randomized controlled trial

Search Period	Citation	Risk of Bias	N Study Design
October 24 to November 26, 2023	Pramhas S, Thalhammer T, Turner S, et al. Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. <i>Lancet Reg Health Eur.</i> 2023;35. doi: 10.1016/j.lanepe.2023.100777. PMID: 38033459.	Moderate	86 Randomized controlled trial
September 3 to October 1, 2023	Hansen JS, Gustavsen S, Roshanisehat H, et al. Cannabis-based medicine for neuropathic pain and spasticity—a multicenter, randomized, double-blinded, placebo-controlled trial. <i>Pharmaceuticals (Basel).</i> 2023a;16(8):1079. doi: 10.3390/ph16081079. PMID: 37630995.	Low	134 Randomized controlled trial
April 24 to May 21, 2023	Schubert EA, Johnstone MT, Benson MJ, et al. Medicinal cannabis for Australian patients with chronic refractory pain including arthritis. <i>Br J Pain.</i> 2023;17(2):206-17. doi: 10.1177/20494637221147115. PMID: 37057257.	High	296 Prospective cohort

Note: The first study listed is in bold because it was identified in the current search period.

Suggested citation: Chou R, Ahmed AY, Bougatsos C, Morasco BJ, Dana T, Fu R. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update—Surveillance Report 4. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 75Q80120D00006.) AHRQ Publication No. 24-EHC33. Rockville, MD: Agency for Healthcare Research and Quality; August 2024. DOI: <https://doi.org/10.23970/AHRQEPCCER250.2023UPDATESR4>. Posted final reports are located on the Effective Health Care Program [search page](#).